NCT03668522

Brief Summary

H3F3AK27M may be a feature of primary spinal cord glioma and affect the outcome and prognosis of TMZ chemoradiotherapy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2018

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

September 3, 2018

Completed
9 days until next milestone

First Posted

Study publicly available on registry

September 12, 2018

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2020

Completed
Last Updated

September 12, 2018

Status Verified

September 1, 2018

Enrollment Period

1.3 years

First QC Date

September 3, 2018

Last Update Submit

September 11, 2018

Conditions

Spinal Tumor

Keywords

H3F3AK27M

Outcome Measures

Primary Outcomes (1)

  • positive

    positive of H3F3AK27M

    through study completion, an average of 1 year

Study Arms (2)

children

age\<=17

Other: Genetic testing

adult

age\>17

Other: Genetic testing

Interventions

Genetic testingOTHER

To determine whether H3F3AK27M exist in spinal glioma

adultchildren

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Surgical treatment and pathological confirmation of spinal glioma in our department.

You may qualify if:

  • Surgical treatment and pathological confirmation of spinal glioma in our department and is the first case without any treatment before operation.

You may not qualify if:

  • The tumor is recurrent or has been treated before operation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nan fang hospital, Southern medical university

Guangzhou, Guangdong, 510515, China

RECRUITING

MeSH Terms

Conditions

Spinal Cord Neoplasms

Interventions

Genetic Testing

Condition Hierarchy (Ancestors)

Central Nervous System NeoplasmsNervous System NeoplasmsNeoplasms by SiteNeoplasmsSpinal Cord DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Clinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative TechniquesGenetic TechniquesGenetic ServicesHealth ServicesHealth Care Facilities Workforce and ServicesDiagnostic ServicesPreventive Health Services

Study Officials

  • Lu Yuntao, M.D., Ph.D

    Nanfang Hospital Neurosurgery Department

    STUDY CHAIR

Central Study Contacts

Lu Yuntao, M.D., Ph.D

CONTACT

13632101002lllu2000@163.com

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
adjunct professor

Study Record Dates

First Submitted

September 3, 2018

First Posted

September 12, 2018

Study Start

September 1, 2018

Primary Completion

January 1, 2020

Study Completion

January 1, 2020

Last Updated

September 12, 2018

Record last verified: 2018-09

Locations

CN(1)